Form 4: Aurinia CFO Michael Hearne Receives Equity Grant

Aurinia Pharmaceuticals CFO Michael S. Hearne was granted 116,144 performance stock units and 70,230 stock options.

Summary

• CFO Michael S. Hearne acquired 116,144 performance stock units (PSUs) on May 18, 2026.
• The reporting person was also granted 70,230 employee stock options with an exercise price of $15.28.
• The PSUs are subject to performance-based vesting conditions tied to share price targets and retention periods.
• The stock options vest 33% after one year, with the remainder vesting monthly over the following two years.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding executive compensation, which is expected in the normal course of business.

Positives

• Equity-based compensation aligns the CFO's interests with long-term shareholder value creation.
• Vesting schedules for PSUs are tied to achieving progressively higher share price targets, incentivizing performance.

Negatives

• The grant results in potential future dilution for existing shareholders upon the vesting and exercise of these equity instruments.

Risks

• Vesting of performance units is contingent upon achieving specific share price targets which may not be met.
• Market volatility could impact the value of the granted equity and the likelihood of meeting performance hurdles.

Future Outlook

The equity grants indicate management's focus on long-term performance targets and retention through multi-year vesting schedules.

Management Comments

• The filing does not contain narrative management commentary beyond the required disclosure of transaction details.

Industry Context

StockSavvy.ai notes that equity grants to C-suite executives in the biopharmaceutical sector are standard practice to ensure alignment with long-term clinical and commercial milestones.

Comparison to Industry Standards

• The use of performance-based vesting tied to share price targets is consistent with governance best practices for mid-cap biotech firms.
• The three-year vesting schedule for options is standard for executive compensation packages in the industry.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise of these options and vesting of units.

Next Steps

• Vesting of 33% of stock options on May 18, 2027.
• Monitoring of share price performance against the four target price tranches for PSU vesting.

Key Dates

Keywords

Aurinia Pharmaceuticals, AUPH, Form 4, Insider Trading, Equity Compensation, CFO, Stock Options